Valuation: Vectura Group

Market Cap 1B 884M 823M 756M 1.42B 96.34B 1.44B 9.77B 3.82B 47.56B 3.77B 3.69B 164B P/E 2019
-27.3x
P/E 2020 6.2x
Enterprise Value 930M 818M 762M 700M 1.31B 89.21B 1.33B 9.04B 3.53B 44.04B 3.49B 3.42B 152B EV / Sales 2019
2.8x
EV / Sales 2020 3.49x
Free-Float
-
Yield 2019 *
-
Yield 2020 -
25-10-30 Liquidia Technologies, Inc. Enters into an Exclusive Licensing Agreement with Vectura Limited CI
24-09-16 Molex Asia Holdings Ltd. signed an agreement to acquire Vectura Group plc from Vectura Fertin Pharma, Inc. for £300 million. CI
24-04-16 Mundipharma and Vectura Announce Plans to Reformulate Fluticasone Propionate/Formoterol Fumarate CI
21-12-28 EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation CI
21-12-03 Philip Morris CEO does not need M&A to hit smoke free goals RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION" RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION" RE
Manager TitleAgeSince
Chief Executive Officer - -
Chief Tech/Sci/R&D Officer - 2016-05-31
Corporate Secretary - 2025-06-29
Director TitleAgeSince
Director/Board Member 53 2023-09-14
Director/Board Member 57 2025-06-29

Financials

2019 2020
Net sales 178M 157M 146M 134M 252M 17.1B 255M 1.73B 677M 8.44B 669M 655M 29.2B 191M 168M 156M 143M 269M 18.28B 273M 1.85B 724M 9.02B 715M 700M 31.21B
Net income -22.1M -19.44M -18.1M -16.63M -31.21M -2.12B -31.64M -215M -83.94M -1.05B -82.96M -81.16M -3.62B 122M 108M 100M 92.1M 173M 11.74B 175M 1.19B 465M 5.79B 459M 450M 20.04B
Net Debt -66.5M -58.49M -54.47M -50.04M -93.92M -6.38B -95.19M -647M -253M -3.15B -250M -244M -10.89B -74.4M -65.44M -60.94M -55.98M -105M -7.13B -107M -723M -283M -3.52B -279M -273M -12.18B
Logo Vectura Group
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.
Employees
-
Sector
-